SWOT Analysis for Kala Pharmaceuticals Inc

Relative Strength Index (RSI) Bullish
High Normalized Momentum Score
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Stock gained more than 20% in one month
Annual Net Profits improving for last 2 years
Stock with Low PE (PE < = 10)
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

Companies with High Debt
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Top Losers
Low Piotroski Score : Companies with weak financials
Declining profits every quarter for the past 2 quarters
Top Losers